Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 51 min ago
Peer-reviewedCC BY-NC-NDPreventive medicine reports

Cost-effectiveness and cost-benefit analysis of the thalassaemia prevention programme in Guangdong, southern China.

  • Li Bing1
  • Wu Jing2
  • Wang Xionghu3
  • Du Li2
  • Luo Can4
  • Yin Aihua2,5,6
6 affiliations
  1. 1Maternal and Child Health Research Institute, Guangdong Women and Children Hospital, Guangzhou, China.
  2. 2Medical Genetic Center, Guangdong Women and Children Hospital, Guangzhou, China.
  3. 3Department of Health Care, Guangdong Women and Children Hospital, Guangzhou, China.
  4. 4Administration Office, Guangdong Women and Children Hospital, Guangzhou, China.
  5. 5Guangzhou Key Laboratory of Prenatal Screening and Prenatal Diagnosis, Guangzhou, China.
  6. 6Maternal and Children Metabolic-Genetic Key Laboratory, Guangzhou, China.
Read full textPDFDOICite

Abstract

This study aimed to evaluate the cost-effectiveness and economic benefits of the Guangdong thalassaemia prevention programme (GDTPP) to provide evidence for optimizing the prevention of thalassaemia. We used the archived data of 2,987,437 couples of GDTPP in China between 2015 and 2024, and calculated prevention costs and therapy costs under blood transfusion and iron-chelation (BTIC) and hematopoietic stem cell transplantation (HSCT) for β- thalassaemia major (TM). Sensitivity analyses were conducted. Among all participation, 11,997 (0.40%) couples were identified as both carrying β0 or α0-thalassaemia mutations. Prenatal diagnosis identified 3976 α-TM and 1566 β-TM affected fetuses. Assuming treatment under BTIC or HSCT, the total prevention cost was 498,267,571 RMB or 430,862,571 RMB, which was lower than the expected postpartum therapy costs of 1,631,851,866 RMB or 616,888,116 RMB. Sensitivity analysis showed that when the proportion of β-TM terminations exceeded 23.90% (BTIC) or 63.20% (HSCT), the total prevention cost was lower than the expected treatment cost. Cost-effectiveness also varied across regions. The GDTPP is cost-effective and has achieved favorable outcomes. Curative treatments for TM can reduce prevention costs and improve quality of life, and they have the potential to reshape future thalassaemia prenatal prevention strategies in China.

Related

  1. Thalassaemia prevention in Asia: progress, challenges, and future directions.
    Michael Angastiniotis, Suthat Fucharoen, Kittiphong Paiboonsukwong +11
    The Lancet regional health. Southeast AsiaPeer-reviewedCC BY-NC-NDFull textHuman geneticsEurope PMC
  2. ‘Tizz Time’: a School-Based Trauma-Informed Violence Prevention Programme
    Sophie Badger, Dean Wilkinson, Isha Chopra
    Journal of Child & Adolescent TraumaPeer-reviewedLicence not statedFull textPsychiatry & mental healthPMC
  3. Assessing the impact of a sugar prevention programme on caries
    C. A. Feldens, P. F. Kramer, M. R. Vítolo +1
    British Dental JournalPeer-reviewedLicence not statedFull textGeneral biologyEpidemiology & public healthHAL
  4. Development and content validation of a risk-stratified nursing intervention programme for the prevention of healthcare-associated infections
    Luís Filipe Pereira Todo Bom, Maria dos Anjos Coelho Rodrigues Dixe, Maria do Céu Marquês
    Journal of Infection PreventionPeer-reviewedLicence not statedFull textInfectious diseasePMC
  5. Estimating the cost-effectiveness of the National Weight Management Enhanced Service and NHS Digital Weight Management Programme in England: a modelling study
    Ben Amies-Cull, Stella Haffner, Peter Scarborough +3
    BMJ OpenPeer-reviewedCC BY 4.0Full textGeneral medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{bing2026costeffectiveness,
  title = {{Cost-effectiveness and cost-benefit analysis of the thalassaemia prevention programme in Guangdong, southern China.}},
  author = {Li Bing and Wu Jing and Wang Xionghu and Du Li and Luo Can and Yin Aihua},
  journal = {Preventive medicine reports},
  year = {2026},
  month = oct,
  doi = {10.1016/j.pmedr.2026.103683},
  url = {https://europepmc.org/article/MED/42997737},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Cost-effectiveness and cost-benefit analysis of the thalassaemia prevention programme in Guangdong, southern China.
AU  - Li Bing
AU  - Wu Jing
AU  - Wang Xionghu
AU  - Du Li
AU  - Luo Can
AU  - Yin Aihua
PY  - 2026
DA  - 2026/10/27
JO  - Preventive medicine reports
DO  - 10.1016/j.pmedr.2026.103683
UR  - https://europepmc.org/article/MED/42997737
AB  - This study aimed to evaluate the cost-effectiveness and economic benefits of the Guangdong thalassaemia prevention programme (GDTPP) to provide evidence for optimizing the prevention of thalassaemia. We used the archived data of 2,987,437 couples of GDTPP in China between 2015 and 2024, and calculated prevention costs and therapy costs under blood transfusion and iron-chelation (BTIC) and hematopoietic stem cell transplantation (HSCT) for β- thalassaemia major (TM). Sensitivity analyses were conducted. Among all participation, 11,997 (0.40%) couples were identified as both carrying β0 or α0-thalassaemia mutations. Prenatal diagnosis identified 3976 α-TM and 1566 β-TM affected fetuses. Assuming treatment under BTIC or HSCT, the total prevention cost was 498,267,571 RMB or 430,862,571 RMB, which was lower than the expected postpartum therapy costs of 1,631,851,866 RMB or 616,888,116 RMB. Sensitivity analysis showed that when the proportion of β-TM terminations exceeded 23.90% (BTIC) or 63.20% (HSCT), the total prevention cost was lower than the expected treatment cost. Cost-effectiveness also varied across regions. The GDTPP is cost-effective and has achieved favorable outcomes. Curative treatments for TM can reduce prevention costs and improve quality of life, and they have the potential to reshape future thalassaemia prenatal prevention strategies in China.
SN  - 2211-3355
ER  -